Blueprint Medicines Corp Stock
Blueprint Medicines Corp Stock
Pros and Cons of Blueprint Medicines Corp in the next few years
Pros
Cons
Performance of Blueprint Medicines Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | - | - | - | - | - | - | - |
| United Therapeutics | 0.440% | -3.323% | 11.062% | 57.242% | 6.202% | 116.095% | 217.343% |
| Iovance Biotherapeutics Inc. | -2.990% | -6.756% | 31.924% | -0.844% | 36.151% | -45.686% | -87.748% |
| Ligand Pharmaceuticals | -2.750% | -2.732% | 12.658% | 78.894% | 7.229% | 183.801% | 36.765% |
News
Offshore Titans: Transocean Buys Valaris for $5.8B
Transocean Ltd. (NYSE: RIG) has made the definitive move to cement its status as the undisputed leader in offshore drilling. By agreeing to acquire Valaris Limited (NYSE: VAL) in an all-stock
Why Ford's Deal With Amazon Is Bigger Than You Think
Ford Motor Company (NYSE: F) has made a groundbreaking move in automotive retail, announcing a partnership to sell its certified pre-owned (CPO) vehicles directly on Amazon (NASDAQ: AMZN).
This
Time to Take Notice: PEGA’s GenAI Blueprint Delivers Huge Q3 Beat
On a day that saw a handful of highly impressive earnings reports, tech stock Pegasystems (NASDAQ: PEGA) more than held its own. Shares blasted up by 15% on Oct. 22 as the market digested the

